Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release

AAPS J. 2009 Mar;11(1):120-2. doi: 10.1208/s12248-009-9086-3. Epub 2009 Feb 19.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adjuvants, Pharmaceutic / administration & dosage*
  • Adjuvants, Pharmaceutic / pharmacokinetics
  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biotransformation
  • Carboxylesterase / blood
  • Carboxylesterase / deficiency
  • Carboxylesterase / genetics
  • Carboxylesterase / physiology
  • Culture Media
  • Dexamethasone / administration & dosage
  • Dexamethasone / analogs & derivatives*
  • Dexamethasone / pharmacokinetics
  • Drug Delivery Systems
  • Esterases / blood
  • Esterases / physiology*
  • Esters / blood
  • Esters / pharmacokinetics
  • Humans
  • Hydrolysis
  • Macrophages / metabolism
  • Mice
  • Mice, Knockout
  • Mice, Nude
  • Nanoparticles / administration & dosage*
  • Opsonin Proteins / metabolism
  • Plasma
  • Prodrugs / administration & dosage*
  • Prodrugs / pharmacokinetics*
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Distribution
  • Xenograft Model Antitumor Assays

Substances

  • Adjuvants, Pharmaceutic
  • Anti-Inflammatory Agents
  • Culture Media
  • Esters
  • Opsonin Proteins
  • Prodrugs
  • Dexamethasone
  • Esterases
  • Carboxylesterase